MCID: TNG004
MIFTS: 37

Tongue Disease

Categories: Gastrointestinal diseases, Oral diseases, Smell/Taste diseases

Aliases & Classifications for Tongue Disease

MalaCards integrated aliases for Tongue Disease:

Name: Tongue Disease 12 15
Abnormality of the Tongue 29 6
Tongue Diseases 44 73
Tongue Disorders 43

Classifications:



External Ids:

Disease Ontology 12 DOID:10944
ICD10 33 K14 K14.9
ICD9CM 35 529.9
MeSH 44 D014060
UMLS 73 C0040409

Summaries for Tongue Disease

MedlinePlus : 43 Your tongue helps you taste, swallow, and chew. You also use it to speak. Your tongue is made up of many muscles. The upper surface contains your taste buds. Problems with the tongue include Pain Swelling Changes in color or texture Abnormal movement or difficulty moving the tongue Taste problems These problems can have many different causes. Treatment depends on the underlying problem.

MalaCards based summary : Tongue Disease, also known as abnormality of the tongue, is related to glossitis and ankyloglossia, and has symptoms including glossalgia, halitosis and oral manifestations. An important gene associated with Tongue Disease is TBX22 (T-Box 22), and among its related pathways/superpathways are Cytoskeletal Signaling and Striated Muscle Contraction. The drugs Cefuroxime and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include tongue, lung and colon.

Wikipedia : 76 Tongue diseases can be congenital or acquired, and are multiple in number. Considered according to a... more...

Related Diseases for Tongue Disease

Graphical network of the top 20 diseases related to Tongue Disease:



Diseases related to Tongue Disease

Symptoms & Phenotypes for Tongue Disease

UMLS symptoms related to Tongue Disease:


glossalgia, halitosis, oral manifestations, snoring, peeling tongue

Drugs & Therapeutics for Tongue Disease

Drugs for Tongue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefuroxime Approved Phase 4,Not Applicable 55268-75-2 5361202 5479529
2
Doxycycline Approved, Investigational, Vet_approved Phase 4,Not Applicable 564-25-0 54671203
3
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
4
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
5 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2,Not Applicable
6 Anti-Infective Agents Phase 4,Phase 1,Phase 2,Not Applicable
7 Antimalarials Phase 4,Not Applicable
8 Antiparasitic Agents Phase 4,Not Applicable
9 Antiprotozoal Agents Phase 4,Not Applicable
10 cefuroxime axetil Phase 4,Not Applicable
11 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2,Not Applicable
12 penicillins Phase 4
13
Cetuximab Approved Phase 2, Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
14
Cisplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
15
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
16 Antibodies Phase 2, Phase 3,Phase 1,Not Applicable
17 Immunoglobulins Phase 2, Phase 3,Phase 1,Not Applicable
18 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1,Not Applicable
19 Antimitotic Agents Phase 2, Phase 3,Phase 1
20
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
21
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
22
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
23
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
24
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
25
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
26
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
27
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
28
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
29
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
30
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
31
Famotidine Approved Phase 2 76824-35-6 3325
32
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
33
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
34
Hydroxyurea Approved Phase 2,Phase 1 127-07-1 3657
35
nivolumab Approved Phase 2 946414-94-4
36
Promethazine Approved, Investigational Phase 2 60-87-7 4927
37
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
38
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1,Not Applicable 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 2,Not Applicable 58-05-9 143 6006
41
Inulin Approved, Investigational, Nutraceutical Phase 2 9005-80-5 24763
42 Raspberry Approved, Nutraceutical Phase 1, Phase 2,Not Applicable
43
Niacin Approved, Investigational, Nutraceutical Phase 2,Phase 1 59-67-6 938
44
Nicotinamide Approved, Investigational, Nutraceutical Phase 2,Phase 1 98-92-0 936
45
Saracatinib Investigational Phase 2 379231-04-6
46
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
47
Camptothecin Experimental Phase 2 7689-03-4
48 Micronutrients Phase 2,Phase 1,Not Applicable
49 Trace Elements Phase 2,Phase 1,Not Applicable
50 Vitamin B Complex Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome Completed NCT01518192 Phase 4 doxycycline;cefuroxime axetil
2 Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice Completed NCT01368341 Phase 4 Doxycycline;Phenoxymethylpenicillin;Amoxicillin
3 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
4 Inulin and S. Salivarius Reduce Halitosis Completed NCT02794766 Phase 2 Inulin+SS;S salivarius;Placebo
5 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
6 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
7 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed NCT01195922 Phase 1, Phase 2 Sirolimus
8 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
9 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
10 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
11 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
12 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
13 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
14 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
15 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
16 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
17 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Recruiting NCT03107182 Phase 2 nab-paclitaxel;Carboplatin;Nivolumab;Cisplatin;Hydroxyurea;5-FU;Dexamethasone;Famotidine;Diphenhydramine;Paclitaxel
18 S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Recruiting NCT03499808 Phase 2
19 Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
20 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Recruiting NCT03008330 Phase 1, Phase 2
21 Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Recruiting NCT02985255 Phase 2 Docetaxel;Cisplatin;5FU
22 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Recruiting NCT02849379 Phase 1, Phase 2
23 Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
24 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
25 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
26 A Study of Tongue Conservation Surgery for Oral Tongue Cancer Terminated NCT03161548 Phase 2 Induction chemotherapy
27 Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity Withdrawn NCT02295540 Phase 1, Phase 2
28 Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer Withdrawn NCT01953952 Phase 2 cisplatin
29 Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
30 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel
31 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
32 TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
33 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
34 Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Completed NCT00049283 Phase 1 erlotinib hydrochloride;docetaxel
35 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer Recruiting NCT01847326 Phase 1 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;fluorouracil;hydroxyurea
36 Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Terminated NCT01528137 Phase 1
37 Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Terminated NCT00906360 Phase 1 sunitinib malate
38 Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy Withdrawn NCT01728480 Phase 1 entolimod;cisplatin
39 Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy Withdrawn NCT01332279 Phase 1 everolimus;erlotinib hydrochloride
40 HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome Unknown status NCT01931293 Not Applicable
41 Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer Unknown status NCT01854021 Not Applicable
42 The Relationship Between Allergic Rhinitis and Geographic Tongue Unknown status NCT01454492
43 Culture Media for Borrelia Burgdorferi Sensu Lato Completed NCT02145754 Not Applicable
44 Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High-Risk Appalachian Patients Previously Treated With Surgery For Oral Cancer Completed NCT01504932 Not Applicable lyophilized black raspberry lozenge
45 Doxycycline in Therapy of Erythema Migrans Completed NCT01475708 Doxycycline
46 Duration of Antibiotic Treatment of Erythema Migrans Completed NCT00910715 Not Applicable doxycycline;doxycycline;placebo
47 Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Completed NCT00594724 Not Applicable
48 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
49 Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue Recruiting NCT02584270 Not Applicable
50 Isolation and Establishment of Gustatory Cell Lines in Patients Operated on for Cancer of the Mobile Tongue - ImmortTasteCELL Recruiting NCT03305302

Search NIH Clinical Center for Tongue Disease

Cochrane evidence based reviews: tongue diseases

Genetic Tests for Tongue Disease

Genetic tests related to Tongue Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Tongue 29

Anatomical Context for Tongue Disease

MalaCards organs/tissues related to Tongue Disease:

41
Tongue, Lung, Colon

Publications for Tongue Disease

Articles related to Tongue Disease:

# Title Authors Year
1
Tongue disease in advanced AIDS. ( 15752079 )
2005

Variations for Tongue Disease

ClinVar genetic disease variations for Tongue Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(3;17)(p14.3;q24.3)dn Translocation Likely pathogenic

Expression for Tongue Disease

Search GEO for disease gene expression data for Tongue Disease.

Pathways for Tongue Disease

Pathways related to Tongue Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.29 KRT6A KRT6B SRCIN1
2 10.81 TNNI2 TNNT3

GO Terms for Tongue Disease

Cellular components related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 troponin complex GO:0005861 8.62 TNNI2 TNNT3

Biological processes related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cardiac muscle contraction GO:0060048 9.37 TNNI2 TNNT3
2 muscle filament sliding GO:0030049 9.32 TNNI2 TNNT3
3 skeletal muscle contraction GO:0003009 9.26 TNNI2 TNNT3
4 regulation of muscle contraction GO:0006937 9.16 TNNI2 TNNT3
5 cornification GO:0070268 9.13 KRT6A KRT6B TMEM79
6 muscle contraction GO:0006936 8.8 MYH13 TNNI2 TNNT3

Molecular functions related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.36 GLYAT IL36RN IRF6 KRT6A KRT6B MYH13
2 actin binding GO:0003779 9.13 MYH13 TNNI2 TNNT3

Sources for Tongue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....